[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342698-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342698-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognosis-of-biopsy-confirmed-metabolic-dysfunction-associated-steatotic-liver-disease-a-sub-analysis-of-the-clione-study","Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease - A sub-analysis of the CLIONE study","","Metabolic dysfunction-associated steatotic liver disease (MASLD) was evaluated as an alternative concept to nonalcoholic fatty liver disease (NAFLD) using biopsy-confirmed cases from a multicenter CLIONE study sub-analysis. Among 1,398 NAFLD patients, ~99% met MASLD criteria (n=1,381). Those without cardiometabolic risk (n=17) had lower BMI and markedly less severe histologic inflammation, ballooning, NAFLD activity, and fibrosis, with no deaths or major events during 5.9 years median follow-up. Overall MASLD prognosis was comparable to the original cohort. ",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognosis-of-biopsy-confirmed-metabolic-dysfunction-associated-steatotic-liver-disease-a-sub-analysis-of-the-clione-study/342698/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognosis-of-biopsy-confirmed-metabolic-dysfunction-associated-steatotic-liver-disease-a-sub-analysis-of-the-clione-study/342698.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were patients classified as MASLD in this study?","Question",{"text":63,"@type":64},"Patients with NAFLD were diagnosed using liver biopsy and were classified as MASLD if they met at least one cardiometabolic criterion.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What proportion of NAFLD patients met MASLD criteria?",{"text":68,"@type":64},"Approximately 99% of cases (n=1,381) met MASLD criteria, while 17 patients did not have cardiometabolic risk.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key prognostic findings for patients with pure MASLD?",{"text":72,"@type":64},"The prognosis for pure MASLD was similar to that of the original CLIONE cohort, and the leading causes of death included extrahepatic cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342698,1790653465,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","pISSN 2287-2728 eISSN 2287-285X  \nOriginal Article  \n[https://doi.org/10.3350/cmh.2023.0515](https://doi.org/10.3350/cmh.2023.0515)[ ](https://doi.org/10.3350/cmh.2023.0515)Clinical and Molecular Hepatology 2024;30:225-234  \nPrognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis ofthe CLIONE study  \nMichihiro Iwaki1, Hideki Fujii2, Hideki Hayashi3, Hidenori Toyoda4 , Satoshi Oeda5, Hideyuki Hyogo6, Miwa Kawanaka7, Asahiro Morishita8, Kensuke Munekage9,10, Kazuhito Kawata11, Tsubasa Tsutsumi12, Koji Sawada13, Tatsuji Maeshiro14 , Hiroshi Tobita15, Yuichi Yoshida16, Masafumi Naito16, Asuka Araki17,  \nShingo Arakaki14 , Takumi Kawaguchi12, Hidenao Noritake11, Masafumi Ono18, Tsutomu Masaki8, Satoshi Yasuda4 ,  \nEiichi Tomita3, Masato Yoneda1, Akihiro Tokushige19, Yoshihiro Kamada20, Hirokazu Takahashi21, Shinichiro Ueda19, Shinichi Aishima22, Yoshio Sumida23, Atsushi Nakajima1, and Takeshi Okanoue24 ;  \nJapan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)  \n1Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan; 2 Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan; 3 Department of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, Japan; 4 Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan; 5 Liver Center and Department of Laboratory Medicine, Saga University Hospital, Saga, Japan; 6 Hyogo Life Care Clinic Hiroshima, Hiroshima, Japan; 7 Department of General Internal Medicine2, Kawasaki Medical Center, Kawasaki Medical School, Okayama, Japan; 8 Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan; 9 Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan; 10 Department of Gastroenterology, Kochi Prefectural Hata Kenmin Hospital, Kochi, Japan; 11Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Shizuoka, Japan; 12 Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan; 13 Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan; 14 Department of Gastroenterology, Urasoe General Hospital, Okinawa, Japan; 15 Department of Hepatology, Shimane University Hospital, Shimane, Japan; 16 Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka, Japan; 17 Division of Pathology, Shimane University Hospital, Shimane, Japan; 18 Division of Innovative Medicine for Hepatobiliary & Pancreatology, Faculty of Medicine, Kagawa University, Kagawa, Japan; 19 Department of Clinical Pharmacology and Therapeutics School of Medicine University of the Ryukyus, Okinawa, Japan; 20 Department of Advanced Metabolic Hepatology, Osaka University, Graduate School of Medicine, Osaka, Japan; 21Liver Center, Saga University Hospital, Saga, Japan; 22 Department of Scientific Pathology Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 23Graduate School of Healthcare Management, International University of Healthcare and Welfare, Tokyo, Japan; 24 Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Suita, Japan  \nGraphical Abstract  \nCopyright © 2024 by Korean Association for the Study of the Liver  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/3.0/](http://creativecommons.org/licenses/by-nc/3.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nClinical and Molecular Hepatology Volume_30 Number_ 2 April 2024  \nStudy Highlights  \n• What is already known about this topic?  \nMASLD was recently proposed as an alt","cbCaiugKoUlWd8hX","https://ap.wps.com/l/cbCaiugKoUlWd8hX","pdf",2620608,11,"English","# Background/Aims\n# Methods\n# Results\n# Study Highlights\n## What is already known\n## What does this study add\n## How may this study affect research, practice, or policy","[{\"question\":\"How were patients classified as MASLD in this study?\",\"answer\":\"Patients with NAFLD were diagnosed using liver biopsy and were classified as MASLD if they met at least one cardiometabolic criterion.\"},{\"question\":\"What proportion of NAFLD patients met MASLD criteria?\",\"answer\":\"Approximately 99% of cases (n=1,381) met MASLD criteria, while 17 patients did not have cardiometabolic risk.\"},{\"question\":\"What were the key prognostic findings for patients with pure MASLD?\",\"answer\":\"The prognosis for pure MASLD was similar to that of the original CLIONE cohort, and the leading causes of death included extrahepatic cancer.\"}]","Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease - A sub-analysis of the CLIONE study | PDF",1790047755,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e71b8a059062807af13624f3d6ab9c1.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9dc05fee7d1276d4862e31fb9eb5b0c.webp",982,1299,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8adf5c6f2f46d549ae39a61c3bafce3f.webp",981,1298,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26c4852d7fbe895ef298f86c449d6ee7.webp",980,1297]